Amir Mehdizadeh

Amir Mehdizadeh

Auto-generated profile, based on publicly available information

Amir Mehdizadeh

Hematology and Oncology Research Center Tabriz University of Medical Sciences Tabriz Iran

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2022 in Cell Biology International
Verified
Journal Article
Closed access
MRMortaza Raeisi
Mortaza Raeisi
MZMojtaba Zehtabi
Mojtaba Zehtabi
KVKobra Velaei
Kobra Velaei
PFParisa Fayyazpour
Parisa Fayyazpour
NANegar Aghaei
Negar Aghaei
AMAmir Mehdizadeh
Amir Mehdizadeh

1 January 2014 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
FMFatemeh Mohammadzadeh
Fatemeh Mohammadzadeh
GMGholamali Mosayebi
Gholamali Mosayebi
VMVahid Montazeri
Vahid Montazeri
MDMaryam Darabi
Maryam Darabi
SFShabnam Fayezi
Shabnam Fayezi
MDMasoud Darabi
Masoud Darabi
Mohammadzadeh F, et al. J Breast Cancer. 2014 Jun;17(2):136-142. https://doi.org/10.4048/jbc.2014.17.2.136

1 October 2020 in International Immunopharmacology
Verified
Journal Article
Closed access
SDShahla Danaii
Shahla Danaii
FGFarzaneh Ghorbani
Farzaneh Ghorbani
MAMajid Ahmadi
Majid Ahmadi
HAHossein Abbaszadeh
Hossein Abbaszadeh
LKLadan Koushaeian
Ladan Koushaeian
MYMehdi Yousefi
Mehdi Yousefi

29 June 2020 in Iranian Journal of Allergy, Asthma and Immunology
Verified
Journal Article
Open access
PDF file
APAlireza Pishgahi
Alireza Pishgahi
RARozita Abolhasan
Rozita Abolhasan
SSSeyed Kazem Shakouri
Seyed Kazem Shakouri
MSMohammad Sadegh Soltani-Zangbar
Mohammad Sadegh Soltani-Zangbar
SDShahla Dareshiri
Shahla Dareshiri
MYMehdi Yousefi
Mehdi Yousefi
Knee osteoarthritis (OA) is one of the common degenerative articular disorders that are related to decreased quality of life. Currently, novel biologic therapeutic approaches are introduced in the literature for OA management. In this study, the clinical efficiency of Dextrose prolotherapy, platelet-rich plasma (PRP) and autologous conditioned serum (ACS) injection on the level of pain and function in Knee OA were compared. A randomized clinical trial was directed on 92 knee OA patients. Patients were randomly divided into three groups: 30 were received dextrose prolotherapy once in a week for three weeks, 30 received autologous PRP for two times with seven days interval, and in the remaining 32 patients 2ml of ACS were injected two times every seven days. Study participants were measured through the Western Ontario and McMaster Universities (WOMAC) score, the visual analogue scale (VAS), at baseline, 1 and 6 months post-intervention. Both ACS and PRP treated patients showed improvement in pain intensity and knee function during 1 and 6 months pursue; however, this progress was more significant in the ACS group. Dextrose prolotherapy showed no substantial changes in pain and function of the affected knee in treated patients. Treatment of Knee OA with ACS and PRP injections are associated with pain reduction and knee function improvement. Not only, ACS therapy is more effective than that of PRP, but also due to its less variability in processing and less reported side effects, it could be considered as a safe and effective non-surgical alternative for OA management.

17 February 2017 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
ARAysa Rezabakhsh
Aysa Rezabakhsh
ENElahe Nabat
Elahe Nabat
MYMina Yousefi
Mina Yousefi
SMSoheila Montazersaheb
Soheila Montazersaheb
OCOmid Cheraghi
Omid Cheraghi
AGAlireza Garjani
Alireza Garjani

1 January 2017 in Neuroscience Letters
Verified
Journal Article
Closed access
NANima Abdyazdani
Nima Abdyazdani
ANAlireza Nourazarian
Alireza Nourazarian
HCHojjatollah Nozad Charoudeh
Hojjatollah Nozad Charoudeh
MKMasoumeh Kazemi
Masoumeh Kazemi
NFNavid Feizy
Navid Feizy
RRReza Rahbarghazi
Reza Rahbarghazi